Half-year report · HY
2112.TEDINET S100WZFP
Period2025-04-01 → 2025-09-30
Filed2025-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥32.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥16.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥1.4bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.5bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.2bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.5bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.5bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥30.5bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥29.4bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥26.7bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥12.3bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥12.8bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥18.2bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥16.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥14.4bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.9bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.9bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥869m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥520m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥372m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥55.21 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.91 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.53 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 59.6% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-04-01 → 2025-09-30 | ¥68m |
| Otherother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥60m |
| Otherother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥8m |
| Otherother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥38m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥82m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥82m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥723m |
| Biotechnologyreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥847m |
| Biotechnologyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥807m |
| Biotechnologyreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥39m |
| Biotechnologyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥160m |
| Sugarreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥15.8bn |
| Sugarreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥15.8bn |
| Sugarreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥35m |
| Sugarreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥16.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥82m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥2.2bn |
| Otherother segments | revenue | 2024-04-01 → 2024-09-30 | ¥67m |
| Otherother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥59m |
| Otherother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥8m |
| Otherother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥39m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥62m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥62m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥701m |
| Biotechnologyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥838m |
| Biotechnologyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥799m |
| Biotechnologyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥39m |
| Biotechnologyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥186m |
| Sugarreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.3bn |
| Sugarreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.3bn |
| Sugarreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥14m |
| Sugarreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥16.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥16.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥62m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥2.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 498
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of investment securities inv cf | Prior1InterimDuration | -0 | JPY |
| Purchase of investment securities inv cf | InterimDuration | -0 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1InterimDuration | 82000000 | JPY |
| Proceeds from sales of investment securities inv cf | InterimDuration | 1310000000 | JPY |
| Payments of loans receivable inv cf | Prior1InterimDuration | -1000000 | JPY |
| Payments of loans receivable inv cf | InterimDuration | -480000000 | JPY |
| Collection of loans receivable inv cf | Prior1InterimDuration | 463000000 | JPY |
| Collection of loans receivable inv cf | InterimDuration | 415000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | Prior1InterimDuration | -500000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | InterimDuration | － | JPY |
| Other net inv cf | Prior1InterimDuration | -0 | JPY |
| Other net inv cf | InterimDuration | 2000000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | -372000000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | 869000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1InterimDuration | -400000000 | JPY |
| Net increase decrease in short term loans payable fin cf | InterimDuration | -300000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1InterimDuration | 700000000 | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration | 300000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -1200000000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -844000000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -247000000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -409000000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -1147000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -1253000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -1000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | -1000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | 484000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | 634000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 2305000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 3313000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 2789000000 | JPY |
| Cash and cash equivalents | InterimInstant | 3947000000 | JPY |
| Products warehouse and transportation expenses sga | Prior1InterimDuration | 498000000 | JPY |
| Products warehouse and transportation expenses sga | InterimDuration | 504000000 | JPY |
| Sales promotion expenses sga | Prior1InterimDuration | 5000000 | JPY |
| Sales promotion expenses sga | InterimDuration | 5000000 | JPY |
| Payrolls allowances and compensation sga | Prior1InterimDuration | 221000000 | JPY |
| Payrolls allowances and compensation sga | InterimDuration | 243000000 | JPY |
| Provision for compensation sga | Prior1InterimDuration | 49000000 | JPY |
| Provision for compensation sga | InterimDuration | 48000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 11000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 9000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00361-000SugarReportableSegmentsMember | 15303000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00361-000BiotechnologyReportableSegmentsMember | 799000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OtherReportableSegmentsMember | 59000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 16162000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 16162000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00361-000SugarReportableSegmentsMember | 14000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00361-000BiotechnologyReportableSegmentsMember | 39000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |